Portable Exoskeleton for Parkinson's Disease Mobility (NCT06028529)

Migration, Crosslink

📖

Portable Exoskeleton for Parkinson's Disease Mobility (NCT06028529)

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-portable-exoskeleton-p

📖 Wiki Page

clinical708 wordssynced 2026-04-02

Overview

flowchart TD therapeutics_portable_exoskele["Portable Exoskeleton for Parkinsons Disease Mobi"] therapeutics_portable_exoskele["trial"] therapeutics_portable_exoskele -->|"related to"| therapeutics_portable_exoskele style therapeutics_portable_exoskele fill:#81c784,stroke:#333,color:#000 therapeutics_portable_exoskele["investigates"] therapeutics_portable_exoskele -->|"related to"| therapeutics_portable_exoskele style therapeutics_portable_exoskele fill:#81c784,stroke:#333,color:#000 therapeutics_portable_exoskele["feasibility"] therapeutics_portable_exoskele -->|"related to"| therapeutics_portable_exoskele style therapeutics_portable_exoskele fill:#81c784,stroke:#333,color:#000 therapeutics_portable_exoskele["safety"] therapeutics_portable_exoskele -->|"related to"| therapeutics_portable_exoskele style therapeutics_portable_exoskele fill:#81c784,stroke:#333,color:#000 style therapeutics_portable_exoskele fill:#4fc3f7,stroke:#333,color:#000

This clinical trial investigates the feasibility and safety of a portable exoskeleton device to improve mobility in patients with Parkinson's disease (PD). The study is sponsored by the VA Office of Research and Development, reflecting the significant burden of movement disorders among Veterans and the Department's commitment to developing innovative rehabilitation technologies["@nct"][@vaoffices].

...

Overview

Mermaid diagram (expand to render)

This clinical trial investigates the feasibility and safety of a portable exoskeleton device to improve mobility in patients with Parkinson's disease (PD). The study is sponsored by the VA Office of Research and Development, reflecting the significant burden of movement disorders among Veterans and the Department's commitment to developing innovative rehabilitation technologies["@nct"][@vaoffices].

Portable exoskeletons represent a promising frontier in [neurorehabilitation](/therapeutics/neurorehabilitation-neurodegeneration) for neurodegenerative diseases, offering device-based assistance that can be used in daily life settings rather than limited to clinical environments.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06028529 |
| Title | Portable Exoskeleton for Parkinson's Disease Mobility |
| Status | Not Yet Recruiting / Recruiting |
| Phase | Not Applicable (Feasibility Study) |
| Sponsor | VA Office of Research and Development |
| Mechanism | Device-based rehabilitation |
| Intervention | Portable exoskeleton device |
| Estimated Enrollment | Variable (typical feasibility: 20-50 participants) |
| Study Design | Single-group or randomized controlled trial |

Conditions Studied

The trial targets patients with:

Idiopathic Parkinson's disease (PD)
Parkinsonian syndromes with mobility impairments
Gait dysfunction secondary to dopaminergic neurodegeneration

Mechanism of Action

Exoskeleton-Assisted Rehabilitation

Portable exoskeletons for Parkinson's disease operate through several mechanisms to improve mobility:

Mechanical Assistance — The device provides external torque to assist leg movements during walking, helping overcome bradykinesia and rigidity

Postural Support — Lightweight frames assist with balance and postural stability

Gait Normalization — Robotic guidance promotes more normal walking patterns

Sensory Feedback — Some devices provide proprioceptive cues that may help with movement initiation

Why Exoskeletons for PD

[Parkinson's disease](/diseases/parkinsons-disease) affects mobility through:

[Dopaminergic neuron loss](/neurons/dopaminergic-neurons) in the [substantia nigra pars compacta](/brain-regions/substantia-nigra)
[Basal ganglia](/brain-regions/basal-ganglia) circuitry disruption affecting motor initiation
Bradykinesia — Slowness of movement that makes walking difficult
Freezing of gait — Sudden inability to initiate movement
Postural instability — Balance difficulties increasing fall risk

Traditional dopaminergic medications ([levodopa](/therapeutics/levodopa), [dopamine agonists](/therapeutics/dopamine-agonists)) effectively treat resting tremor and bradykinesia but often incompletely address gait dysfunction and freezing of gait. Exoskeletons offer a complementary mechanical approach.

Comparison with Other Rehabilitation Devices

| Device Type | Mechanism | Advantages | Limitations |
|-------------|-----------|-------------|-------------|
| Portable Exoskeleton | Mechanical joint assistance | Ambulatory, daily use | Requires user tolerance |
| tDCS | Electrical brain modulation | Non-invasive | Session-based |
| CUE1 Device | Vibrotactile cueing | Wearable, continuous | Sensory-dependent |
| Virtual Reality | Visual/sensory cueing | Engaging | Fixed environment |
| Deep Brain Stimulation | Neural modulation | Effective for motor symptoms | Invasive, surgical |

Clinical Significance

Current Treatment Gap

Despite advances in [Parkinson's disease pharmacology](/therapeutics/parkinsons-treatment-overview):

Gait disorders remain partially refractory to dopaminergic medications
Freezing of gait affects up to 50% of PD patients after 5-10 years
Fall risk increases significantly with disease progression
Quality of life is severely impacted by mobility limitations

Potential Benefits of Portable Exoskeletons

Non-pharmacological — No drug interactions or side effects

Complementary — Can be used alongside standard medications

Daily use — Portable devices allow practice in real-world settings

Neuroplasticity — May promote motor learning and neural reorganization

Independence — Potentially reduces caregiver burden

Research Challenges

Weight and bulk — Devices must be lightweight enough for PD patients
Battery life — Extended use requires adequate power
User acceptance — Comfort and ease of use are critical
Cost — Reimbursement and accessibility considerations

External Links

[ClinicalTrials.gov NCT06028529](https://clinicaltrials.gov/study/NCT06028529)
[VA Office of Research and Development](https://www.research.va.gov/)
[PubMed - Gait in Parkinson's Disease](https://pubmed.ncbi.nlm.nih.gov/)

References

[NCT06028529 - Portable Exoskeleton for Parkinson's Disease Mobility (n.d.)](/[NCT06028529](https://clinicaltrials.gov/study/NCT06028529))

[VA Office of Research and Development (n.d.)](/[VA Research](https://www.research.va.gov/))

[Exoskeletons for Gait Rehabilitation in Neurological Disorders - Arch Phys Med Rehabil (n.d.)](https://pubmed.ncbi.nlm.nih.gov/)

[MDS-UPDRS - Movement Disorder Society Unified Parkinson's Disease Rating Scale (n.d.)](/[MDS-UPDRS](https://www.movementdisorders.org/MDS.htm))

[Gait in Parkinson's Disease - Nat Rev Neurol (n.d.)](https://pubmed.ncbi.nlm.nih.gov/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineering](/hypothesis/h-24e08335) — 0.52 · Target: TDC
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1
[Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — 0.71 · Target: HSPA1A
[Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation](/hypothesis/h-fb56c8a0) — 0.69 · Target: SDC1
[Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — 0.65 · Target: PRMT1
[TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficki](/hypothesis/h-98b431ba) — 0.64 · Target: TFAM
[Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation](/hypothesis/h-9eae33ba) — 0.56 · Target: KCNK2
[HSP90-Tau Disaggregation Complex Enhancement](/hypothesis/h-0f00fd75) — 0.55 · Target: HSP90AA1

📖 View canonical wiki page →

Related Entities

therapeutics-portable-exoskeleton-pd-nct06028529

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-portable-exoskeleton-pd-nct06028529
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1ab013fa568c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-portable-exoskeleton-pd-nct06028529'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

84

Outgoing

104

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Portable Exoskeleton for Parkinson's Disease Mobility (NCT06028529)

Overview

Overview

Trial Details

Conditions Studied

Mechanism of Action

Exoskeleton-Assisted Rehabilitation

Why Exoskeletons for PD

Comparison with Other Rehabilitation Devices

Clinical Significance

Current Treatment Gap

Potential Benefits of Portable Exoskeletons

Research Challenges

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Portable Exoskeleton for Parkinson's Disease Mobility (NCT06028529)

Overview

Overview

Trial Details

Conditions Studied

Mechanism of Action

Exoskeleton-Assisted Rehabilitation

Why Exoskeletons for PD

Comparison with Other Rehabilitation Devices

Clinical Significance

Current Treatment Gap

Potential Benefits of Portable Exoskeletons

Research Challenges

See Also

Related Diseases

External Links

References

Related Hypotheses

💬 Discussion